RESUMO
AIMS: Type 1 diabetes (T1D) is a growing chronic disease. Evidence of whether the healthcare setting affects management and glycemic control is scarce. We evaluate outcomes in patients with T1D in private and public healthcare settings in Mexico, registered in the National T1D Registry in Mexico (RENACED-DT1). METHODS: Biochemical parameters, diabetes education, and treatment were analyzed considering the data registered in the last visit. Development of chronic complications was determined during follow-up. RESULTS: We included 1,603 patients; 71.5% (n = 1,146) registered in the public system, and 28.5% (n = 457) in a private institution. Patients in the public setting had higher HbA1c (8.6%, IQR: 7.3%-10.5% vs 7.7%, IQR: 7.0%-8.8%; p < 0.001). Indicators of diabetes education, glucose monitoring, and use of insulin-pumps were lower in the public setting. Patients in the public setting were at higher risk of diabetic chronic kidney disease, retinopathy, and neuropathy. Diabetes knowledge was a mediator between type of healthcare setting and the likelihood of achieving glycemic control. CONCLUSIONS: Patients registered in public healthcare settings have an adverse metabolic profile and higher risk of complications. Social factors need to be addressed in order to implement multidisciplinary measures focused on diabetes education for patients with T1D in Mexico.
Assuntos
Diabetes Mellitus Tipo 1 , Glicemia , Automonitorização da Glicemia , Atenção à Saúde , Diabetes Mellitus Tipo 1/complicações , Diabetes Mellitus Tipo 1/tratamento farmacológico , Diabetes Mellitus Tipo 1/epidemiologia , Hemoglobinas Glicadas/análise , Controle Glicêmico , Humanos , México/epidemiologiaRESUMO
Background: Information regarding diagnosis, treatment, and follow-up of patients with type 1 diabetes (PWT1D) in Mexico is limited. We developed an on-line platform Registro Nacional de Pacientes con Diabetes Tipo 1 (RENACED-DT1). Objective: The objective of the study was to describe the characteristics and healthcare of PWT1D registered in RENACED-DT1. Methods: Analyses of 965 PWT1D from July 2014 to January 2018 in different endocrinology clinics around Mexico. Results: Sixty-one percent were female with median age of 21 years, age at diagnosis 11 years, and disease duration at inclusion 8.2 years. Treatment regimen was basal-bolus in 61% and insulin-pumps in 21% (mainly in the private sector); 33.3% with self-monitoring of blood-glucose (SMBG) ≥4 times/day. Mean HbA1c at last follow-up was 8.7 ± 2.1% (72±23 mmol/mol), 18% had HbA1c < 7% (53 mmol/mol), and 35% > 9% (75 mmol/mol). SMBG ≥ 4 times/day was associated with HbA1c < 7%. Time since diagnosis > 10 years, female sex, BMI ≥ 30 kg/m2, SMBG < 4 times/day, and any hypoglycemia were associated with microvascular complications (p < 0.05). Conclusions: Percentage of patients achieving HbA1c < 7% is low; increased blood glucose monitoring is associated with better glycemic control. The achievement of optimal glycemic control must be increased to reduce the incidence of chronic complications and improve quality of life in PWT1D.
Assuntos
Humanos , Masculino , Feminino , Criança , Adolescente , Adulto Jovem , Diabetes Mellitus Tipo 1/terapia , Diabetes Mellitus Tipo 1/epidemiologia , Qualidade de Vida , Glicemia , Hemoglobinas Glicadas/análise , Automonitorização da Glicemia , Sistema de Registros , Hipoglicemiantes , Insulina , México/epidemiologiaRESUMO
BACKGROUND: Information regarding diagnosis, treatment, and follow-up of patients with type 1 diabetes (PWT1D) in Mexico is limited. We developed an on-line platform Registro Nacional de Pacientes con Diabetes Tipo 1 (RENACED-DT1). OBJECTIVE: The objective of the study was to describe the characteristics and healthcare of PWT1D registered in RENACED-DT1. METHODS: Analyses of 965 PWT1D from July 2014 to January 2018 in different endocrinology clinics around Mexico. RESULTS: Sixty-one percent were female with median age of 21 years, age at diagnosis 11 years, and disease duration at inclusion 8.2 years. Treatment regimen was basal-bolus in 61% and insulin-pumps in 21% (mainly in the private sector); 33.3% with self-monitoring of blood-glucose (SMBG) ≥4 times/day. Mean HbA1c at last follow-up was 8.7 ± 2.1% (72±23 mmol/mol), 18% had HbA1c < 7% (53 mmol/mol), and 35% > 9% (75 mmol/mol). SMBG ≥ 4 times/day was associated with HbA1c < 7%. Time since diagnosis > 10 years, female sex, BMI ≥ 30 kg/m2, SMBG < 4 times/day, and any hypoglycemia were associated with microvascular complications (p < 0.05). CONCLUSIONS: Percentage of patients achieving HbA1c < 7% is low; increased blood glucose monitoring is associated with better glycemic control. The achievement of optimal glycemic control must be increased to reduce the incidence of chronic complications and improve quality of life in PWT1D.
Assuntos
Diabetes Mellitus Tipo 1 , Adolescente , Glicemia , Automonitorização da Glicemia , Criança , Diabetes Mellitus Tipo 1/epidemiologia , Diabetes Mellitus Tipo 1/terapia , Feminino , Hemoglobinas Glicadas/análise , Humanos , Hipoglicemiantes , Insulina , Masculino , México/epidemiologia , Qualidade de Vida , Sistema de Registros , Adulto JovemRESUMO
BACKGROUND: Diabetes is a serious health problem for pediatrics. In pediatric patients control depends on correct insulin administration. The most usual is subcutaneous administration according to the glycemic control. The aim was to analyze the indications for continuous subcutaneous insulin infusion (CSII) in type 1 diabetes mellitus (T1DM) children and adolescents. METHODS: It was carried out a descriptive study in patients from 1 to 16 years with T1DM who underwent CSII therapy. The main cause to use this therapy was analyzed, and also if that cause was different regarding age, sex and disease progression. RESULTS: 61 patients underwent CSII therapy. The median age at the beginning of treatment was 9 years old; 43 patients (71.6 %) had more than one year of diagnosis. The main reasons to use CSII were: 42.6 % had to improve their quality of life, 34.4 % had to reduce the high glycemic variability, 13.1 % had to control severe recurrent hypoglycemia, and 9.8 % had to control their HbA1c. For children under 6 years of age (n = 14) the more frequent indication were recurrent hypoglycemia and to improve their quality of life; children from 6 to 12 years of age (n = 27) had to improve their quality of life, and in children over 12 years CSII was indicated for high glycemic variability and severe recurrent hypoglycemia. There was no different indication related between sexes. CONCLUSION: Improve their quality of life and reach a better glycemic control were the main reasons to start CSII in our patients.
Introducción: la diabetes es un problema serio de salud para la pediatría. En pacientes de ese grupo etario, el control depende de la adecuada administración de la insulina.Se buscó analizar las indicaciones para el uso de terapia de infusión continua subcutánea de insulina (ICSI) en niños y adolescentes con diabetes mellitus 1 (DM1). Métodos: estudio descriptivo en pacientes de 1 a 16 años con DM1, en quienes se propuso el inicio de la terapia con ICSI. Se analizó el motivo principal para justificar su inicio y si este fue diferente según edad, sexo y tiempo de evolución. Resultados: en 61 pacientes se aceptó el inicio de ICSI. La mediana de edad fue de 9 años al momento de la colocación y 43 pacientes (71.6 %) tuvieron más de un año de diagnóstico. Los motivos principales para su inicio fueron: 42.6 % (26 de 61) ante un deseo de mejorar su calidad de vida; 34.4 % (21 de 61) para reducir una variabilidad glucémica importante; 13.1 % (8 de 61) para controlar hipoglucemias recurrentes, y 9.8 % (6 de 61) para lograr metas de control en su valor de HbA1c. En los menores de 6 años (n = 14) se indicó más por hipoglucemias recurrentes y para mejorar su calidad de vida; para los de 6 a 12 años (n = 27) para mejorar su calidad de vida; y en los mayores de 12 años (n = 20) por variabilidad glucémica importante e hipoglucemias recurrentes. No hubo diferencias por sexos. Conclusión: los principales motivos que influyeron en la indicación de la ICSI en nuestros pacientes pediátricos fueron mejorar su calidad de vida y lograr un mejor control glucémico.